APTNOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
ADAPTIN BIO, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$6.27+0.00 (0.00%)
Close on Aug 19, 2026
- Market cap
- $55.48M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns Adaptin Bio's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Simon Pedder | 928,571 | 11.50% | 13D (active) | Feb 11, 2025 |
| Michael J. Roberts | 2,159,468 | 26.70% | 13D (active) | Feb 11, 2025 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Simon Pedder | Executive Chairman, Director, 10% owner | 928,571 | 10.06% | Sep 10, 2025 |
| Michael J. Roberts | President and CEO, Director, 10% owner | 2,159,468 | 23.39% | Sep 10, 2025 |
| L. Arthur Hewitt | Chief Development Officer | – | – | Sep 10, 2025 |
| Timothy Maness | Chief Financial Officer | – | – | Sep 10, 2025 |
| Anthony P. Zook | Director | – | – | Sep 10, 2025 |
| J. Nick Riehle | Director | – | – | Sep 10, 2025 |
| Patrick Joseph Gallagher | Director | – | – | Sep 10, 2025 |
| Partners LLC Lucius | 10% owner | 3,250,000 | 35.20% | Feb 13, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Partners LLC Lucius 10% owner | Feb 11, 2025 | Other | −1,750,000 | – | – | 3,250,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.